1. 1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Issue 3 (September 2015) Authors: Zielinski, C.C.; Lang, I.; Inbar, M.; Kahan, Z.; Greil, R.; Beslija, S.; Stemmer, S.M.; Zvirbule, Z.; Steger, G.G.; Melichar, B.; Pienkowski, T.; Sirbu, D.; Petruzelka, L.; Eniu, A.; Nisenbaum, B.; Dank, M.; Anghel, R.; Messinger, D.; Brodowicz, T. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S263 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2732 Is there still room for robotic surgery after radio-chemotherapy for patients with cervical and endometrial cancer?. (September 2015) Authors: Anghel, R.; Vasilescu, C.; Serbanescu, L.; Gales, L.; Mitrica, R.; Trifanescu, O. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S541 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P-074Distant outcome of patients with locally advanced unresectable and metastatic esophageal cancer after multimodality treatment. (21st June 2016) Authors: Gruia, I.; Trifanescu, O.; Bara, M.; Moldoveanu, V.; Anghel, R.; Toma, R.; Gales, L.; Constantinoiu, S. Journal: Annals of oncology Issue: Volume 27(2016)Supplement 2 Page Start: ii23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗